+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Middle East & Africa Bladder Cancer Therapeutics & Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997372
  • Report
  • March 2020
  • Region: Africa, Middle East
  • 85 Pages
  • Mordor Intelligence

FEATURED COMPANIES

  • AstraZeneca Plc.
  • Bristol Myers Squibb
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc.
  • Johnson and Johnson
  • Merck & Co., Inc.
The bladder cancer therapeutics and diagnostics market will witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing innovation in drug development. Based on the data from the International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. In countries in the Middle East and Africa (MEA) region like the United Arab Emirates (UAE), the bladder cancer is 8th most common type of cancer, as per Globocan 2018 data.

In recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developing regions such as Middle East and Africa. Also, the rise of different therapies such as immunotherapy in cancer treatment has rekindled interest among eligible patients as it is a recently developed treatment modality, and has lower side effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management.

Hence, the increasing awareness about bladder cancer and related therapies, the Middle East and Africa bladder cancer therapeutics and diagnostics market is expected to grow in the coming future.

Key Market Trends

Radiation Therapy is Expected to Cover a Large Share of the Market

Bladder cancer is highly prevalent diseases and it increases with age. As per a 2018 Globocan report, the bladder cancer incidence in the Middle East and Africa region is expected to increase in the future. The most advanced modalities of bladder cancer therapeutics include immunotherapy but, the most widely used modality in bladder cancer is radiation therapy. This is due to historical use-prevalence of radiation therapies in various forms of cancers and also because chemotherapy is associated with low specificity and side-effects. Radiation therapy also, offers best in class efficacy, in terms of dose frequency and pricing, when compared to other therapeutic modalities in bladder cancer management. Advancements in radiation therapy and expected increase in number of bladder cancer patients is expected to help the growth of this market.

Competitive Landscape

Most of the global players are present in the Gulf Cooperation Council (GCC) region of the Middle East and Africa (MEA) owing to factors such as economic growth in the last few decades.

The Africa region consists of some developing and underdeveloped countries. The healthcare systems in these countries are still not well structured and stable, due to the lack of essential funds. However, with recent foreign investments, the healthcare scenario is improving in the region. Hence the market in this region, though not large, is expected to grow in the future.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.


This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc.
  • Bristol Myers Squibb
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc.
  • Johnson and Johnson
  • Merck & Co., Inc.

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies
4.2.2 Innovations in Drug Development
4.3 Market Restraints
4.3.1 Rise in the number of Patent Expirations
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Superficial Bladder Cancer
5.1.3 Invasive Bladder Cancer
5.1.4 Other Rare Types
5.2 By Diagnostics and Therapeutics
5.2.1 By Therapeutics
5.2.1.1 Chemotherapy
5.2.1.2 Immunotherapy
5.2.1.3 Radiation Therapy
5.2.1.4 Surgery
5.2.2 By Diagnostics
5.2.2.1 Cytoscopy
5.2.2.2 Biopsy
5.2.2.3 Urinalysis
5.2.2.4 Others
5.3 Geography
5.3.1 Middle East and Africa
5.3.1.1 GCC
5.3.1.2 South Africa
5.3.1.3 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca Plc.
6.1.2 Bristol Myers Squibb
6.1.3 Eli Lilly and Co.
6.1.4 GlaxoSmithKline Plc.
6.1.5 Merck & Co., Inc.
6.1.6 Johnson and Johnson
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Sanofi S.A.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AstraZeneca Plc.
  • Bristol Myers Squibb
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Johnson and Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
Note: Product cover images may vary from those shown

Loading
LOADING...